SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
- PMID: 28919060
- DOI: 10.1016/S2213-8587(17)30315-7
SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
Comment on
-
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.Lancet Diabetes Endocrinol. 2017 Nov;5(11):864-876. doi: 10.1016/S2213-8587(17)30308-X. Epub 2017 Sep 14. Lancet Diabetes Endocrinol. 2017. PMID: 28919061 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical